(Q53519441)

15 May 2018

title

Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). (English)

1 reference

15 May 2018

chronic renal insufficiency

main subject

1 reference

based on heuristic

inferred from title

author name string

Guideline development group

series ordinal

1

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 May 2015

1 reference

15 May 2018

Nephrology Dialysis Transplantation

published in

1 reference

15 May 2018

volume

30 Suppl 2

1 reference

15 May 2018

page(s)

ii1-142

1 reference

15 May 2018

Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

What guidelines should or should not be: implications for guideline production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

European Renal Best Practice (ERBP) Guideline development methodology: towards the best possible guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Asking the right question and finding the right answers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

The impact of dialysis modality on quality of life: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Quality of life assessed with the Medical Outcomes Study Short Form 36-Item Health Survey of patients on renal replacement therapy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Convective versus diffusive dialysis therapies for chronic kidney failure: an updated systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

High-flux or low-flux dialysis: a position statement following publication of the Membrane Permeability Outcome study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

A randomized, controlled trial of early versus late initiation of dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Early initiation of peritoneal dialysis in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Timing of dialysis initiation and survival in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Impact of timing of initiation of dialysis on mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Association between estimated glomerular filtration rate at initiation of dialysis and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Timing of peritoneal dialysis initiation and mortality: analysis of the Canadian Organ Replacement Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Vascular access surgery managed by renal physicians: the choice of native arteriovenous fistulas for hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Vascular access outcomes in the elderly hemodialysis population: A USRDS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Type of vascular access and mortality in U.S. hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Cephalic arch stenosis in patients with fistula access for hemodialysis: relationship to diabetes and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Autogeneous elbow fistulas: the effect of diabetes mellitus on maturation, patency, and complication rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Determinants of haemodialysis access survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Relationship of hemodialysis access to finger gangrene in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Associations between hemodialysis access type and clinical outcomes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

KHA-CARI Guideline: vascular access - central venous catheters, arteriovenous fistulae and arteriovenous grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Re-envisioning Fistula First in a patient-centered culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Comparison of arteriovenous fistulas and arteriovenous grafts in patients with favorable vascular anatomy and equivalent access to health care: is a reappraisal of the Fistula First Initiative indicated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Cardiovascular outcomes after kidney-pancreas and kidney-alone transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Simultaneous pancreas-kidney transplantation and living related donor renal transplantation in patients with diabetes: is there a difference in survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Improved patient survival in recipients of simultaneous pancreas-kidney transplant compared with kidney transplant alone in patients with type 1 diabetes mellitus and end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Improved survival rate in patients with diabetes and end-stage renal disease in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Enhanced posttransplant management of patients with diabetes improves patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Pancreas after living donor kidney versus simultaneous pancreas-kidney transplant: an analysis of the organ procurement transplant network/united network of organ sharing database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Living donor kidney versus simultaneous pancreas-kidney transplant in type I diabetics: an analysis of the OPTN/UNOS database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

The impact of simultaneous pancreas-kidney transplantation on long-term patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Simultaneous pancreas-kidney transplantation in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Twelve-month pancreas graft function significantly influences survival following simultaneous pancreas-kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Early pancreas graft failure is associated with inferior late clinical outcomes after simultaneous kidney-pancreas transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Diabetic neuropathy after pancreas transplantation: determinants of recovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of pancreas-kidney transplantation on diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Impact of simultaneous pancreas and kidney transplantation on progression of coronary atherosclerosis in patients with end-stage renal failure due to type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Comparison before and after transplantation of pancreas-kidney and pancreas-kidney with loss of pancreas--a prospective controlled quality of life study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Impact of pancreas transplantation on the quality of life of diabetic renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Contraindications can damage your health--is metformin a case in point?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Metformin in peritoneal dialysis: a pilot experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Incretin-based therapy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

One-year cardiovascular event rates in outpatients with atherothrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Association of diabetes with increased all-cause mortality following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in the contemporary era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

2013 ESC guidelines on the management of stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

A randomized trial of therapies for type 2 diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

The Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Prolonged effectiveness of coronary artery bypass surgery versus drug-eluting stents in diabetics with multi-vessel disease: an updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Comparative effectiveness of revascularization strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Key recommendations and evidence from the NICE guideline for the acute management of ST-segment-elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Coronary intervention for persistent occlusion after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Management of non-ST-segment elevation acute myocardial infarction in patients with chronic kidney disease (from the Korea Acute Myocardial Infarction Registry).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

In-hospital major clinical outcomes in patients with chronic renal insufficiency presenting with acute coronary syndrome: data from a Registry of 8176 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of fibrates in kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Dietary restriction and exercise for diabetic patients with chronic kidney disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of an exercise program on blood biochemical values and exercise stage of chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Aerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISM

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Association of the clusterin gene polymorphisms with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Going from evidence to recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Kidney allograft and patient survival in type I diabetic recipients of cadaveric kidney alone versus simultaneous pancreas kidney transplants: a multivariate analysis of the UNOS database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Comparing mortality of elderly patients on hemodialysis versus peritoneal dialysis: a propensity score approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Factors that influence access to the national renal transplant waiting list

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Social Adaptability Index predicts access to kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Access to renal transplantation in the diabetic population-effect of comorbidities and body mass index

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Neighborhood poverty and racial disparities in kidney transplant waitlisting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Variation between centres in access to renal transplantation in UK: longitudinal cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Obesity impacts access to kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Equity of access to renal transplant waiting list and renal transplantation in Scotland: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Kidney transplantation and wait-listing rates from the international Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Quality of life after organ transplantation in type 1 diabetics with end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Occult metformin toxicity in three patients with profound lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Metformin overdose with a resultant serum pH of 6.59: survival without sequalae

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

The MALAdy of metformin poisoning: Is CVVH the cure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Metformin-induced encephalopathy without lactic acidosis in a patient with contraindication for metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Peritoneal sodium mass removal in continuous ambulatory peritoneal dialysis and automated peritoneal dialysis: influence on blood pressure control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Metformin-associated lactic acidosis treated with continuous renal replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Experiences of a poison center with metformin-associated lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Metformin-associated lactic acidosis precipitated by acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Metformin-associated lactic acidosis with acute renal failure in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Clearance of metformin by hemofiltration in overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Metformin-induced lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Use of urea containing dialysate to avoid disequilibrium syndrome, enabling intensive dialysis treatment of a diabetic patient with renal failure and severe metformin induced lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Intensive care treatment of severe mixed metabolic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Survival after metformin-associated lactic acidosis in peritoneal dialysis--dependent renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Metformin-associated lactic acidosis precipitated by acute renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Successful treatment of severe lactic acidosis caused by a suicide attempt with a metformin overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Does glucose infusion exacerbate metformin-associated lactate acidosis? A case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

High anion gap metabolic acidosis in suicide: don't forget metformin intoxication--two patients' experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Metformin-associated nonketotic metabolic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Strategies for multivessel revascularization in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effect of pravastatin in people with diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Rosuvastatin in diabetic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Influence of antiplatelet medications on bleeding events in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Age and comorbidity may explain the paradoxical association of an early dialysis start with poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Associations between comorbidities, treatment choice and outcome in the elderly with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Cost-Effectiveness of Initiating Dialysis Early: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFV100

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD009008.PUB2

12 January 2024

Identifiers

DOI

10.1093/NDT/GFV100

1 reference

15 May 2018

PubMed ID

25940656

1 reference

15 May 2018